DOCSLIB.ORG

Page11.Qxd (Page 1)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Page11.Qxd (Page 1) DAILY EXCELSIOR, JAMMU FRIDAY, SEPTEMBER 14, 2018 (PAGE 11) 160 Doxylamine + Pyridoxine + Mefenamic Acid + Paracetamol 793 OFFICE OF THE CONTROLLER 161 Dried Alumnium Hydroxie Gel + Prophantheline + Diazepam 1038 162 Drotaverine + Clidinium + Chlordiazepoxide 794 163 Enrofloxacin + Bromhexin 882 DRUG & FOOD CONTROL ORGANIZATION, 164 Ergotamine Tartrate + Belladona Dry Extarct+Caffeine + Paracetamol 1027 165 Ethylmorphine + Noscapine + Chlorpheniramine 924 J&K (SRINAGAR) 166 Famotidine + Oxytacaine + Magaldrate 840 167 Flunarizine + Paracetamole + Domperidone 832 CIRCULAR 168 Flupentixol + Escitalopram 796 169 Furazolidone + Metronidazole + Loperamide 844 The Central Government in exercise of powers conferred under Section 26-A of the 170 Gabapentin + Mecobalamin + Pyridoxine + Thiamine 798 Drugs and Cosmetics Act, 1940 has prohibited the manufacture/sale/or distribution of 171 Gentamicin Sulphate + Clotrimazole + Betamethasone + Lignocaine 829 172 Gentamycin + Dexamethasone + Chloramphenicol + Tobramycin + Ofloxacin 858 the following Fixed Dose Combinations (FDCs) with immediate effect. This prohibition 173 Glibenclamide + Metformin (SR)+ Pioglitazone 822 has been imposed pursuant upon recommendations furnished by the Drugs Technical 174 Gliclazide 40mg + Metformin 400mg 1029 Advisory Board (DTAB) for the reason that these FDCs have no therapeutic justification 175 Gliclazide 80 mg + Metformin 325 mg 803 176 Glimepiride + Pioglitazone + Metformin 815 claimed or purported to be claimed from them: 177 Glimepiride 1mg/2mg/3mg + Pioglitazone 15mg/15mg/15mg + Metformin 1000mg/1000mg/1000mg 806 HIGH COURT OF JAMMU AND KASHMIR AT JAMMU (OFFICE OF THE REGISTRAR JUDICIAL, JAMMU) LIST OF FDC'S BANNED WITH EFFECT FROM 12-09-2018 AS PER NOTIFICATIONS 178 Glimepiride 1mg/2mg+ Pioglitazone 15mg/15mg + Metformin 850mg/850mg 807 179 Glipizide 2.5mg + Metformin 400 mg 816 OWP No. 1652/2018, IA No. 1/2018 SL.NO FIXED DOSE COMBINATION NOTIFICATION NO Inhabitants of Tehsil Thatharka through their representatives 180 Glucosamine + Methyl Sullfonyl Methane + Vitamin D3 + Manganese + Boron + Copper + Zinc 732 1. Mohd Saleem Mulah, 47 years S/o Ghulam Mohammad R/o Block Sangaldan Village Thatharka, District Ramban. 1 Aceclofenac (SR) + Paracetamol 750 181 Guaifenesin + Bromhexine + Chlorpheniramine + Paracetamol 980 2. Mohd Khalil Dar, 72 years S/o Habibullah R/o Block Sangaldan Village Thatharka, District Ramban 2 Aceclofenac + Paracetamol + Famotidine 744 3. Ghulam Hussain 48 years S/o Abdullah R/o Block Sangaldan Village Thatharka, District Ramban 182 Guaifenesin + Bromhexine + Chlorpheniramine + Phenylephrine + Paracetamol + Serratiopeptidase 1000 4. Atta Mohd. Hajam, 45 years S/o Abdul Razaq R/o Block Sangaldan Village Thatharka, District Ramban. 3 Aceclofenac + Paracetamol + Rabeprazole 705 .....Petitioners (as enteric coated granules) 10000 SP Units V/s 4 Aceclofenac + Zinc Carnosine 745 183 Guaifenesin + Dextromethorphan 948 1. State of J&K through Commissioner/Secretary Department of Revenue Govt of J&K, Civil Secretariat, Srinagar 5 Acetaminophen + Guaifenesin + Dextromethorphan + Chlorpheniramine 945 2. The Financial Commissioner Revenue, Jammu & Kashmir, Jammu 184 Guaifenesin + Diphenhydramine + Bromhexine + Phenylephrine 1037 3. The Divisional Commissioner, Jammu 6 Acetaminophen + Loratadine + Ambroxol + Phenylephrine 906 4. The Deputy Commissioner, Ramban 185 Heparin + Diclofenac 731 ...Respondents 7 Acriflavine + Thymol + Cetrimide 1014 186 Imipramine + Chlordiazepoxide + Trifluoperazine + Trihexyphenidyl 799 NOTICE TO PUBLIC AT LARGE 8 Acrivastine + Paracetamol + Caffeine + Phenylephrine 915 PROCLAMATION 187 Ketoconazole + Tea Tree oil + Allantion + Zinc Oxide + Aloe Vera + Jojoba oil +Lavander oil + Soa noodels 1017 In the Matter of : 9 Albuterol + Bromhexine + Theophylline 1033 188 Ketotifen + Cetirizine 939 Whereas, the petitioners, residents of Block Sangaldan Village Thatharka, District Ramban have filed above titled writ peti- 10 Albuterol + Etofylline + Bromhexine + Menthol 1032 tion before the Hon’ble Court seeking direction to non-applicants from the Hon’ble Court for espousing the cause of the res- 189 Ketotifen + Levocetrizine 951 ident of Tehsil Thatharka, i.e Block Sangaldan Village Thatharka, District Ramban. 11 Alginic Acid + Sodium Bicarbonate + Dried Aluminium Hydroxide + Magnesium Hydroxide 842 Whereas, through the medium of this proclamation the public at large is informed that in case the persons interested to pro- 190 Ketotifen + Theophylline 941 cedure the petition has any objection in the issuance of direction in favour of the petitioners with respect to espousing the 12 Allantoin + Dimethieone + Urea + Propylene + Glycerin + Liquid Paraffin 1013 191 L-5-Methyltetrahydrofolate Calcium + Escitalopram 788 cause of the resident of Tehsil Thatharka. He/they shall file their objections in person or through their counsel on or before 13 Ambroxol + Levocetirizine + Phenylephrine + Guaiphenesin + Menthol 956 25.09.2018 in the Hon’ble Court. 192 L-Arginine + Sildenafil 783 Given under my hand and seal of this court on this 11th day of September, 2018. 14 Ambroxol + Guaifenesin + Phenylephrine + Chlorpheniramine 927 Sd/- 193 Levocetirizine + Ambroxol + Phenylephrine + Guaiphenesin 874 Registrar Judicial 15 Ambroxol + Salbutamol + Choline Theophyllinate + Menthol 987 194 Levocetirizine + Ambroxol + Phenylephrine + Paracetamol 1005 High Court of J&K 16 Ambroxol + Salbutamol + Theophylline 942 Jammu 195 Levocetirizine + Dextromethorphan + Zinc 931 No. 13843 17 Ambroxol + Terbutaline + Dextromethorphan 895 Dated : 12/9/18 196 Levocetirizine + Montelukast + Acebrophylline 912 18 Ambroxol+ Guaiphenesin + Ammonium Chloride + Phenylephrine + Chlorpheniramine Maleate + Menthol 872 197 Levocetirizine + Paracetamol + Phenylephirine + Caffeine 949 19 Ammonium Chloride + Dextromethorphan + Cetirizine + Menthol 964 Department of Wildlife Protection J&K Government 198 Levocetirizine + Phenylephrine + Ambroxol + Guaiphenesin + Paracetamol 886 20 Ammonium Chloride + Sodium Citrate + Chlorpheniramine Maleate + Menthol 740 199 Levocetirizine + Ranitidine 885 OFFICE OF THE WILDLIFE WARDEN 21 Ammonium Citrate + Vitamin B 12 + Folic Acid + Zinc Sulphate 1042 200 Levofloxacin + Bromhexine 884 22 Amoxicillin + Cefixime + Potassium Clavulanic Acid 757 (DEPARTMENT OF WILDLIFE PROTECTION) 201 Levofloxacin + Ornidazole + Alpha Tocopherol Acetate 761 23 Amoxicillin + Dicloxacillin 753 202 Levothyroxine + Phyridoxine + Nicotinamide 1043 KATHUA 24 Amoxicillin 250 mg + Potassium Clavulanate Diluted 62.5 754 203 Lignocaine + Clotrimazole + Ofloxacin + Beclomethasone 773 (Tel/Fax No. 01922-234622, Email:[email protected]) 25 Amoxycillin + Dicloxacillin + Serratiopeptidase 771 204 Lornoxicam + Paracetamol + serratiopeptidase 737 26 Amoxycillin + Tinidazole 764 205 Lornoxicam + paracetamol + Tramadol 736 CORRIGENDUM 27 Ascorbic Acid + Manadione Sodium Bisulphate + Rutin + Dibasic Calcium Phosphate + Adrenochrome mono Se 1046 206 Lornoxicam + paracetamol + trypsin 728 28 Atorvastatin + Vitamin D3 + Folic Acid + Vitamin B12 + Pyridoxine 784 207 Magaldrate + Famotidine + Simethicone 834 E-TENDERING cancellation Notice 29 Azithromycin + Acebrophylline 865 208 Magaldrate + Papain + Fungul Diastase + Simethicone 838 30 Azithromycin + Ambroxol 781 209 Magaldrate + Ranitidine + Pancreatin + Domperidone 836 Sub.: Supply of Feed/ Fodder items for Mansar Deer 31 Azithromycin + Cefixime 752 210 Mebeverine & Inner HPMC capsule (Streptococcus Faecalis + Clostridium butyricum + Bacillus mesentricus + Lactic Acid Bacillus) 853 32 Azithromycin + Cefpodoxime 772 Park, Kathua 211 Menthol + Anesthetic Ether 1025 33 Azithromycin + Levofloxacin 755 212 Metformin (SR) 500mg + Pioglitazone 5mg 824 Reference: This office Tender Notice : e-NIT No.:- 01/WLWK 34 Azithromycin + Ofloxacin 763 213 Metformin (Sustainded Release) 500mg + Pioglitazone 15 mg + Glimepiride 3mg 823 35 Becloemthasone + Clotrimazole + Chloramphenicol + Gentamycin + Lignocaine Ear drops 831 of 2018-19 dated: 28-08-2018 & e-tender ID: 214 Metformin + Atorvastatin 785 36 Beclomethasone + Clotimazole + Neomycin + lodochlorohydroxyquinone 1007 215 Metformin + Bromocriptine 812 2018_FD_60303_1. 37 Beclomethasone + Clotrimazole + Gentamicin + lodochlorhydroxyquinoline 1040 216 Metformin + Gliclazide + Chromium Polynicotinate 821 38 Beclomethasone Diproprionate + Neomycin + Tolnaftate + lodochlorhydroxyquinoline + Chlorocresol 1020 217 Metformin + Gliclazide + Piogllitazone + Chromium Polynicotinate 820 39 Benfotiamine + Metformin 1044 218 Metformin + Glimepiride + Methylcobalamin 813 The above referred NIT No. is hereby cancelled due to non- 40 Benzoxonium Chloride + Lidocaine 735 219 Metformin 1000/1000/500/500mg + Pioglitazone 7.5/7.5/7.5/7.5mg + Glimepiride 1/2/1/2mg 802 41 Betahistine + Ginkgo Biloba Extract + Vinpocetine + Piracetam 791 receipt of minimum bids & fresh tender of the same will be float- 220 Metformin 500mg/500mg+Gliclazide SR 30mg/60mg + Pioglitazone 7.5mg/7.5mg 810 42 Betamethasone + Fusidic Acid + Gentamycin + Tolnaftate + lodochlorhydroxyquinoline (ICHQ) 1002 221 Metformin 850mg + Pioglitazone 7.5 mg + Glimepiride 1mg/2 mg 808/809 ed shortly. 43 Betamethasone + Gentamicin + Tolnaftate + lodochlorhydroxyquinoline 1011 222 Metformin ER + Gliclazide MR + Voglibose 818 44 Betamethasone + Gentamycin + Zinc Sulphate + Clotrimoazole + Chlorocresol 1021 223 Metronidazole + Norfloxacin 776 DIP/J-6014/18 Wildlife Warden 45 Betamethasone + Neomycin + Tolnaftate + lodochlorohydroxyquinoline
Load more

Recommended publications
  • Antiseptics and Disinfectants for the Treatment Of
    Verstraelen et al. BMC Infectious Diseases 2012, 12:148 http://www.biomedcentral.com/1471-2334/12/148 RESEARCH ARTICLE Open Access Antiseptics and disinfectants for the treatment of bacterial vaginosis: A systematic review Hans Verstraelen1*, Rita Verhelst2, Kristien Roelens1 and Marleen Temmerman1,2 Abstract Background: The study objective was to assess the available data on efficacy and tolerability of antiseptics and disinfectants in treating bacterial vaginosis (BV). Methods: A systematic search was conducted by consulting PubMed (1966-2010), CINAHL (1982-2010), IPA (1970- 2010), and the Cochrane CENTRAL databases. Clinical trials were searched for by the generic names of all antiseptics and disinfectants listed in the Anatomical Therapeutic Chemical (ATC) Classification System under the code D08A. Clinical trials were considered eligible if the efficacy of antiseptics and disinfectants in the treatment of BV was assessed in comparison to placebo or standard antibiotic treatment with metronidazole or clindamycin and if diagnosis of BV relied on standard criteria such as Amsel’s and Nugent’s criteria. Results: A total of 262 articles were found, of which 15 reports on clinical trials were assessed. Of these, four randomised controlled trials (RCTs) were withheld from analysis. Reasons for exclusion were primarily the lack of standard criteria to diagnose BV or to assess cure, and control treatment not involving placebo or standard antibiotic treatment. Risk of bias for the included studies was assessed with the Cochrane Collaboration’s tool for assessing risk of bias. Three studies showed non-inferiority of chlorhexidine and polyhexamethylene biguanide compared to metronidazole or clindamycin. One RCT found that a single vaginal douche with hydrogen peroxide was slightly, though significantly less effective than a single oral dose of metronidazole.
    [Show full text]
  • Commission Decision of 8 February 2010 Concerning The
    L 36/36 EN Official Journal of the European Union 9.2.2010 COMMISSION DECISION of 8 February 2010 concerning the non-inclusion of certain substances in Annex I, IA or IB to Directive 98/8/EC of the European Parliament and of the Council concerning the placing of biocidal products on the market (notified under document C(2010) 751) (Text with EEA relevance) (2010/72/EU) THE EUROPEAN COMMISSION, concerned should therefore not be included in Annex I, IA or IB to Directive 98/8/EC. Having regard to the Treaty on the Functioning of the European Union, (6) In the interest of legal certainty, biocidal products Having regard to Directive 98/8/EC of the European Parliament containing active substances for the product-types and of the Council of 16 February 1998 concerning the placing indicated in the Annex to this Decision should no of biocidal products on the market ( 1), and in particular the longer be placed on the market, with effect from a second subparagraph of Article 16(2) thereof, specific date. Whereas: (7) The measures provided for in this Decision are in accordance with the opinion of the Standing (1) Commission Regulation (EC) No 1451/2007 of Committee on Biocidal Products, 4 December 2007 on the second phase of the 10-year work programme referred to in Article 16(2) of Directive HAS ADOPTED THIS DECISION: 98/8/EC of the European Parliament and of the Council concerning the placing of biocidal products on the Article 1 market ( 2) establishes a list of active substances to be assessed, with a view to their possible inclusion in The substances indicated in the Annex to this Decision shall not Annex I, IA or IB to Directive 98/8/EC.
    [Show full text]
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • Tonsillopharyngitis - Acute (1 of 10)
    Tonsillopharyngitis - Acute (1 of 10) 1 Patient presents w/ sore throat 2 EVALUATION Yes EXPERT Are there signs of REFERRAL complication? No 3 4 EVALUATION Is Group A Beta-hemolytic Yes DIAGNOSIS Streptococcus (GABHS) • Rapid antigen detection test infection suspected? (RADT) • roat culture No TREATMENT EVALUATION No A Supportive management Is GABHS confi rmed? B Pharmacological therapy (Non-GABHS) Yes 5 TREATMENT A EVALUATE RESPONSEMIMS Supportive management TO THERAPY C Pharmacological therapy • Antibiotics Poor/No Good D Surgery, if recurrent or complicated response response REASSESS PATIENT COMPLETE THERAPY & REVIEW THE DIAGNOSIS© Not all products are available or approved for above use in all countries. Specifi c prescribing information may be found in the latest MIMS. B269 © MIMS Pediatrics 2020 Tonsillopharyngitis - Acute (2 of 10) 1 ACUTE TONSILLOPHARYNGITIS • Infl ammation of the tonsils & pharynx • Etiologies include bacterial (group A β-hemolytic streptococcus, Haemophilus infl uenzae, Fusobacterium sp, etc) & viral (infl uenza, adenovirus, coronavirus, rhinovirus, etc) pathogens • Sore throat is the most common presenting symptom in older children TONSILLOPHARYNGITIS 2 EVALUATION FOR COMPLICATIONS • Patients w/ sore throat may have deep neck infections including epiglottitis, peritonsillar or retropharyngeal abscess • Examine for signs of upper airway obstruction Signs & Symptoms of Sore roat w/ Complications • Trismus • Inability to swallow liquids • Increased salivation or drooling • Peritonsillar edema • Deviation of uvula
    [Show full text]
  • Ulllted States Patent [19] [11] Patent Number: 5,120,325 Dow, Jr
    _ US005120325A Ulllted States Patent [19] [11] Patent Number: 5,120,325 Dow, Jr. [45] Date of Patent: Jun. 9, 1992 [54] COLOR-MATCHED STERILE ADHESIVE 4,561,435 12/1985 McKnight et al. ............... .. 604/304 BANDAGES CONTAINING MELANINLIKE 4,699,792 10/1987 Nick et a1. 1 . .. 604/307 PIGMENT COMPOSITION 4.710,191 12/1987 Kwiatek et a1. 604/304 4,728,323 3/1988 Matson .............. .. ‘604/304 [75] Inventor: James E. Dow, Jr., Hackensack, NJ. 4,745,916 5/1988 Seber ..... .. 128/155 , 4,895,727 l/l990 Allen 424/642 [731 Asslgnw Fleshtones Products (30-11119, 4,990,144 2/1991 Blott .................................. .. 604/304 Hackensack, NJ. Primary Examiner-David Isabella 1211 Appl- N04 713,827 Assistant Examiner—Dinh X. Nguyen [22] Filed: Jam 12, 1991 Attorney, Agent, or Firm-Carl W1 Battle [51] 11.1.0.5 ..................... .. A61F 13/00; A61F 13/02 [57] ABSTRACT [52] U.S. Cl. .................................. .. 604/304; 604/307; A sterile bandage suitable for external application to a 602/41; 602/42; 602/58 wound or injury of the human skin comprising a back [58] Field of Search .............. .. 604/304, 307; 128/156; ing layer, a non-toxic pigmented composition coated 424/447, 448 onto or embedded into the top side of said backing [56] References Cited layer, wherein said pigmented composition comprises one or more pigments having a melanin likeness in ap U.S. PATENT DOCUMENTS pearance so as to substantially match the appearance of said human skin. 3,987,202 10/1976 Okun ................................... .. 424/70 4,161,176 7/1979 Harris, U et a1.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States (2019) Revision 13 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2019) Revision 13 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • B COMMISSION REGULATION (EC) No 1451/2007 of 4 December 2007
    2007R1451 — EN — 01.09.2013 — 002.001 — 1 This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents ►B COMMISSION REGULATION (EC) No 1451/2007 of 4 December 2007 on the second phase of the 10-year work programme referred to in Article 16(2) of Directive 98/8/EC of the European Parliament and of the Council concerning the placing of biocidal products on the market (Text with EEA relevance) (OJ L 325, 11.12.2007, p. 3) Amended by: Official Journal No page date ►M1 Commission Regulation (EU) No 298/2010 of 9 April 2010 L 90 4 10.4.2010 ►M2 Commission Regulation (EU) No 613/2013 of 25 June 2013 L 173 34 26.6.2013 2007R1451 — EN — 01.09.2013 — 002.001 — 2 ▼B COMMISSION REGULATION (EC) No 1451/2007 of 4 December 2007 on the second phase of the 10-year work programme referred to in Article 16(2) of Directive 98/8/EC of the European Parliament and of the Council concerning the placing of biocidal products on the market (Text with EEA relevance) THE COMMISSION OF THE EUROPEAN COMMUNITIES, Having regard to the Treaty establishing the European Community, Having regard to Directive 98/8/EC of the European Parliament and of the Council of 16 February 1998 concerning the placing of biocidal products on the market (1 ), and in particular Article 16(2) thereof, Whereas: (1) Pursuant to Directive 98/8/EC, Member States may only authorise the placing on the market of biocidal products containing active substances included in Annex I, IA or IB to that Directive.
    [Show full text]
  • L:\0901 with Peru\0901PHARMAPPX.Wpd
    Harmonized Tariff Schedule of the United States (2009) (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2009) (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABAPERIDONE 183849-43-6 ACITAZANOLAST 114607-46-4 ABARELIX 183552-38-7 ACITEMATE 101197-99-3 ABATACEPT 332348-12-6 ACITRETIN 55079-83-9 ABCIXIMAB 143653-53-6 ACIVICIN 42228-92-2 ABECARNIL 111841-85-1 ACLANTATE 39633-62-0 ABETIMUS 167362-48-3 ACLARUBICIN 57576-44-0 ABIRATERONE 154229-19-3 ACLATONIUM NAPADISILATE 55077-30-0 ABITESARTAN 137882-98-5 ACODAZOLE 79152-85-5 ABLUKAST 96566-25-5 ACOLBIFENE 182167-02-8 ABRINEURIN 178535-93-8 ACONIAZIDE 13410-86-1 ABUNIDAZOLE 91017-58-2 ACOTIAMIDE 185106-16-5 ACADESINE 2627-69-2 ACOXATRINE 748-44-7 ACAMPROSATE 77337-76-9 ACREOZAST 123548-56-1 ACAPRAZINE 55485-20-6
    [Show full text]
  • 84 Annex V Part a Existing Active Substances, Notification of Which
    Annex V TIME PERIODS AND RAPPORTEUR MEMBER STATES FOR THE SUBMISSION OF COMPLETE DOSSIERS FOR EXISTING ACTIVE SUBSTANCES INCLUDED IN THE REVIEW PROGRAMME Part A Existing active substances, notification of which has been accepted, within product types 8 and 14. For any of these active substances within the specified product type, the complete dossiers must be received by the competent authority of the Rapporteur Member State no later than 28 March 2004. Active substances for wood preservatives Rapporteur Member State Name (EINECS and/or others) EC Number CAS Number Cyclohexylhydroxydiazene 1-oxide, potassium salt - 66603-10-9 A Bis[1-cyclohexyl-1,2-di(hydroxy- - 312600-89-8 A .kappa.O)diazeniumato(2-)]-copper 3-phenoxybenzyl-2-(4-ethoxyphenyl)-2- 407-980-2 80844-07-1 A methylpropylether / Etofenprox Formic acid 200-579-1 64-18-6 B Dazomet 208-576-7 533-74-4 B Zinc oxide 215-222-5 1314-13-2 B .alpha.-cyano-3-phenoxybenzyl 3-(2,2-257-842-9 52315-07-8 B dichlorovinyl)-2,2- dimethylcyclopropanecarboxylate / Cypermethrin [1alpha(S*),3alpha]-(alpha)-cyano-(3- Plant protection 67375-30-8 B phenoxyphenyl)methyl 3-(2,2-dichloroethenyl)-2.2-product dichlorovinyl)-2,2- dimethylcyclopropanecarboxylate / alpha- cypermethrin Propan-2-ol 200-661-7 67-63-0 D L-(+)-lactic acid 201-196-2 79-33-4 D Hexa-2,4-dienoic acid / Sorbic acid 203-768-7 110-44-1 D Calcium dihexa-2,4-dienoate 231-321-6 7492-55-9 D EN 84 EN Active substances for wood preservatives Rapporteur Member State Name (EINECS and/or others) EC Number CAS Number Trimagnesium diphosphide 235-023-7 12057-74-8 D Aluminium phosphide 244-088-0 20859-73-8 D Potassium (E,E)-hexa-2,4-dienoate 246-376-1 24634-61-5 D .alpha.-cyano-4-fluoro-3-phenoxybenzyl 3-(2,2-269-855-7 68359-37-5 D dichlorovinyl)-2,2- dimethylcyclopropanecarboxylate / Cyfluthrin Margosa ext.
    [Show full text]
  • August 28,2003 Dockets Management Branch
    Marling Address, PO. Box 997, Akron, Ohio 44309-0997 August 28,2003 Dockets Management Branch Food and Drug Administration (HFA-305) 5630 Fishers Lane, Room 1061 Rockville, MD 20852 Dear Sir/Madam: Attached is a hard copy of the comments that were emailed to you on August 27, 2003 regarding the Proposed Rule; Reopening of the Administrative Record for Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Health-Care Antiseptic Drug Products. 68 Fed. Reg. 32003. (May29, 2003). [Docket No.75N-183H]. Thank you, GOJO INDUSTRIES, INC. Michael J. Dolan Research and Development Vice President c74 www.GOJO.com August 27,2003 Mailrng Address: PO. Box 991, Akron, Ohm 44309-0991 Dockets Management Branch Food and Drug Administration (HFA-305) 5630 Fishers Lane, Room 1061 Rockville, MD 20852 Re: Proposed Rule; Reopening of the Administrative Record for Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Health-Care Antiseptic Drug Products. 68 Fed. Reg. 32003. (May 29,2003). [Docket No. 75N-183H] Dear Sir/Madam: GOJO Industries, Inc. hereby submits these comments in response to the Food and Drug Administration’s (FDA’s) reopening of the administrative record regarding the tentative final monograph for Over-the-Counter (OTC) Health-Care Antiseptic Drug Products, 59 Fed. Reg. 3 1402 (June 17, 1994) (1994 TFM). These comments address the safety and efficacy of benzalkonium chloride and benzethonium chloride as active antimicrobial agents in leave-on products (products used without water and that are not rinsed off the skin). SUMMARY: The anticipated finalization of the 1994 TFM will be accompanied by a review of the safety and efficacy of the quaternary ammonium compounds (quats), benzalkonium chloride and benzethonium chloride.
    [Show full text]